Aptamers: Chemical antibodies applied nucleotide based therapies
According to a new report published by Reports Monitor titled, “Aptamers Market by Component, Application, and End-User: Global Opportunity Analysis and Industry Forecast, 2017–2025,” the Aptamers market was valued at XX million in 2016, and is projected to reach at XX million by 2025, growing at a CAGR of XX% from 2017 to 2025.
Aptamers are defined as short stretches of RNA or DNA with a particular three-dimensional structure. These structures can form complexes with the target protein in order to halt its expression by blocking its activity. Aptamers have substantial potential to reveal novel applications in the field of research, diagnostic and therapeutic. The common procedure used for selecting precise aptamer with high affinity and specificity with their target molecule, is known as SELEX process.
Strong Trend of R&D investment in pharmaceutical and biotechnological companies and technological advances over the period of time has led the aptamer market to grow tremendously. Furthermore, patient expiration of SELEX process, low cost and high efficiency of aptamers in binding to large molecules further propels the growth of this market and comparatively added benefits provided by aptamers over the well-developed antibodies drives the growth of the aptamer market. However, unmet regulatory policies, reluctance to accept the alternative dearth of trained personnel and less awareness regarding benefits of aptamer may restrict the growth of the market. North America aptamer market growth is majorly driven by swift progression in technology, high expenditure on R&D by pharmaceutical & biotechnological companies and presence of key market players.
The global aptamer market is segmented into on the basis of type, application, technology, end-user and geography. In terms of type the market is separated into DNA based, RNA based and XNA based aptamers. Based on application the market is differentiated into diagnostics, therapeutics development, research & development and other applications. Considering technology segment the market is spilt into SELEX and other technologies. Depending upon end-user the market is categorized into pharmaceutical and biotechnological companies, academic & government research institutes, contract research organizations and other end-users.
Competitive Analysis Manufacturers have adopted various strategies to sustain and maintain their market positions. Expansion is the primary strategy adopted by prominent players in the market, followed by acquisition. The major players operating in the market include Aptamer Science, Inc., AM Biotechnologies, Aptamer Solutions Ltd., NeoVentures Biotechnology, Inc., Aptus Biotech S.L, Aptagen Base Pair Biotechnologies, Inc., SomaLogic, Inc., Vivonics, Inc., TriLink BioTechnologies, Inc. and Noxxon Pharma.
Expansion is the primary strategy adopted by prominent players in the market, followed by acquisition. Aptitude that reveals the hidden potential of aptamers to overcome the basic limitations of antibodies has launched the third aptamer therapeutic program by doing collaborative work with researchers from Johns Hopkins University in 2017.
We at Garner Insights.com provide a comprehensive analysis by providing in-depth reports of the various market verticals. Our Mission is to provide a detailed analysis of the vast markets worldwide backed by rich data. Decision makers can now rely on our well-defined data gathering methods to get the correct and accurate market forecasting along with detailed analysis.